Febuxostat is a novel nonpurine selective inhibitor of xanthine oxidase, which is currently being developed for the management of hyperuricemia in patients with gout. A simple method was developed and validated for the spectrofluorimetric determination of Febuxostat in human plasma. The thiazole moiety in Febuxostat acts as fluorophore which possesses a native fluorescence that could be measured. Febuxostat produces fluorescence at 366 nm (λem) after excitation at 310 nm (λex) in methanol. The calibration graphs were linear in the concentration ranges 50–600 ng/mL. The results were statistically validated and checked through recovery studies. The method was validated and the lower limit of quantification for Febuxostat was found to be 50 ng/mL. The mean recovery for Febuxostat ranged from 95.07 to 97.37%. The sensitivity of the proposed method allows the determination of investigated Febuxostat in human plasma. The statistical comparisons of the results with the reference methods show a proper agreement and indicate no significant difference in accuracy and precision.
Loading....